Asset sale future milestone payments.

No definition available.

Name:	mack_AssetSaleFutureMilestonePayments
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum cumulative obligation for milestone payments under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementMaximumMilestonePaymentObligation
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the cumulative amount of nonrefundable, noncreditable upfront license fees paid during the period under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementUpfrontPaymentObligation
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the maximum cumulative amount of milestone payments that can be received over the life of the license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_MaximumCollaborativeArrangementMilestonePayments
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential milestone payments receivable.

+ References

No definition available.

+ Details

Name:	mack_PotentialMilestonePaymentsReceivable
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Restructuring and related cost number of positions after headcount reduction.

+ References

No definition available.

+ Details

Name:	mack_RestructuringAndRelatedCostNumberOfPositionsAfterHeadcountReduction
Namespace Prefix:	mack_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of a specific restructuring plan and related activities including the facts and circumstances leading to the restructuring or decision to exit an activity, and the expected completion date. This concept and related items would be utilized for each plan if multiple exit plans have been implemented in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(a))
-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Date the restructuring activities were initiated or are expected to be initiated, in CCYY-MM-DD format.

+ References

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesInitiationDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).

+ References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name:	us-gaap_RestructuringCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RestructuringPlanAxis=mack_JanuaryTwoThousandSeventeenCorporateRestructuringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mack_AssetPurchaseAndSaleAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=mack_IpsenSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInPancreasAsFirstLineTreatmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInSmallCellLungCancerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_OtherUnrelatedClinicalTrialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_DevelopmentAndCommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_SaleMilestoneInMajorEuropeanCountriesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_SaleMilestoneInMajorNonEuropeanAndNonAsianCountryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mack_ClinicalTrialsInLungCancerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Sale of Commercial Business - Additional Information (Detail)				3 Months Ended
	Apr. 03, 2017 USD ($) Employee	Jan. 08, 2017 Employee	May 05, 2011 USD ($)	Mar. 31, 2017 USD ($)
January 2017 Corporate Restructuring [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Restructuring activity, announcement date				Jan. 08, 2017
Restructuring and related cost, headcount reduction percentage		30.00%
Restructuring and related cost, number of employees after headcount reduction \| Employee		80
January 2017 Corporate Restructuring [Member] \| Discontinued Operations [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Restructuring expenses				$ 5,300,000
January 2017 Corporate Restructuring [Member] \| Contractual Termination Benefits [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Restructuring expenses				$ 5,300,000
January 2017 Corporate Restructuring [Member] \| One-time Employee Termination Benefits [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Restructuring And Related Activities Description				One-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures. The Company anticipates that the majority of these payments will be made during the second quarter of 2017.
PharmaEngine [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Upfront license fees paid			$ 10,000,000
PharmaEngine [Member] \| Development and Regulatory Milestone [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Maximum milestone payment obligation			80,000,000
PharmaEngine [Member] \| Sales Milestone [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Maximum milestone payment obligation			$ 130,000,000
Subsequent Event [Member] \| Asset Sale Agreement [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Restructuring and related cost, headcount reduction percentage	30.00%
Restructuring and related cost, number of employees after headcount reduction \| Employee	80
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Clinical Trials in Pancreas as First-Line Treatment [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Additional payments receivable on achievement of certain milestone events	$ 225,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Clinical Trials in Small Cell Lung Cancer [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Additional payments receivable on achievement of certain milestone events	150,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Other Unrelated Clinical Trials [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Additional payments receivable on achievement of certain milestone events	75,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Development and Commercialization Milestones [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Maximum amount of milestone payments that can be received	33,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Sale Milestones in Major European Countries [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Potential milestone payments receivable	18,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Sale Milestones in Major Non-European and Non-Asian Country [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Potential milestone payments receivable	5,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Clinical Trials in Lung Cancer [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Potential milestone payments receivable	10,000,000
Subsequent Event [Member] \| Ipsen [Member] \| Asset Sale Agreement [Member] \| Maximum [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Additional payments receivable on achievement of certain milestone events	$ 450,000,000